S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
NASDAQ:SNDX

Syndax Pharmaceuticals Stock Forecast, Price & News

$15.97
+0.12 (+0.76%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.37
$16.10
50-Day Range
$15.85
$20.24
52-Week Range
$13.02
$27.85
Volume
308,646 shs
Average Volume
633,755 shs
Market Capitalization
$788.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.41
30 days | 90 days | 365 days | Advanced Chart
Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Syndax Pharmaceuticals logo

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Headlines

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest Update
November 30, 2021 |  americanbankingnews.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up to $17.08
November 24, 2021 |  americanbankingnews.com
Earnings Preview For Syndax Pharmaceuticals
November 12, 2021 |  benzinga.com
Syndax Pharmaceuticals (SNDX) Set to Announce Earnings on Monday
November 9, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNDX
Employees
43
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.52 million
Book Value
$6.17 per share

Profitability

Net Income
$-73.16 million
Net Margins
-6,031.18%
Pretax Margin
-6,031.18%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,932,000
Market Cap
$788.79 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/14/2022

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

857th out of 1,390 stocks

Pharmaceutical Preparations Industry

407th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

Is Syndax Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syndax Pharmaceuticals stock.
View analyst ratings for Syndax Pharmaceuticals
or view top-rated stocks.

How has Syndax Pharmaceuticals' stock been impacted by Coronavirus?

Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SNDX stock has increased by 35.5% and is now trading at $15.97.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Syndax Pharmaceuticals?

Syndax Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 3,400,000 shares, a decline of 45.8% from the October 31st total of 6,270,000 shares. Based on an average daily volume of 541,200 shares, the days-to-cover ratio is currently 6.3 days. Approximately 8.0% of the company's shares are short sold.
View Syndax Pharmaceuticals' Short Interest
.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for Syndax Pharmaceuticals
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its earnings results on Monday, November, 15th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.24. Syndax Pharmaceuticals had a negative net margin of 6,031.18% and a negative trailing twelve-month return on equity of 44.26%. During the same quarter last year, the firm posted ($0.46) earnings per share.
View Syndax Pharmaceuticals' earnings history
.

What price target have analysts set for SNDX?

8 Wall Street analysts have issued 12 month target prices for Syndax Pharmaceuticals' shares. Their forecasts range from $21.00 to $32.00. On average, they anticipate Syndax Pharmaceuticals' share price to reach $29.57 in the next year. This suggests a possible upside of 85.2% from the stock's current price.
View analysts' price targets for Syndax Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the following people:

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.25%), Wellington Management Group LLP (3.45%), 683 Capital Management LLC (2.34%), Sphera Funds Management LTD. (1.54%), Geode Capital Management LLC (1.51%) and Dimensional Fund Advisors LP (1.33%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Dennis Podlesak, Fabrice Egros, Michael A Metzger, Michael L Meyers and Peter Ordentlich.
View institutional ownership trends for Syndax Pharmaceuticals
.

Which major investors are selling Syndax Pharmaceuticals stock?

SNDX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Millennium Management LLC, Citigroup Inc., Voya Investment Management LLC, Two Sigma Advisers LP, Rafferty Asset Management LLC, Schonfeld Strategic Advisors LLC, and New York State Common Retirement Fund. Company insiders that have sold Syndax Pharmaceuticals company stock in the last year include Briggs Morrison, Fabrice Egros, and Michael A Metzger.
View insider buying and selling activity for Syndax Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Syndax Pharmaceuticals stock?

SNDX stock was acquired by a variety of institutional investors in the last quarter, including Barclays PLC, Morgan Stanley, Sphera Funds Management LTD., Point72 Asset Management L.P., Dimensional Fund Advisors LP, Ensign Peak Advisors Inc, Altium Capital Management LP, and Phoenix Holdings Ltd.. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison, Dennis Podlesak, and Michael L Meyers.
View insider buying and selling activity for Syndax Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $15.97.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals has a market capitalization of $788.79 million and generates $1.52 million in revenue each year. The company earns $-73.16 million in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals employs 43 workers across the globe.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is www.syndax.com.

Where are Syndax Pharmaceuticals' headquarters?

Syndax Pharmaceuticals is headquartered at 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at (781) 419-1400, via email at [email protected], or via fax at 781-419-1420.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.